CELU

Celularity Inc

1.05

Oct 22 • 3:59 PM ET +0.03 (2.94%)

1.05

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano NASD

Today, 8:07 AMCelularity announces it has regained compliance with Nasdaq’s periodic reporting listing requirement following the filing of its delayed second-quarter 2026 Form 10-Q.

Peers: BSEM MDXG PLUR HUMA LCTX MESO VCEL CAPR LGVN ALLO

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	34.07M
Enterprise Value	103.31M
Income	-46.30M
Sales	18.67M
Book/sh	-1.21
Cash/sh	0.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	115
IPO	Aug 08, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	1.83
P/B	-
P/C	57.75
P/FCF	-
EV/EBITDA	-
EV/Sales	5.53
Quick Ratio	0.10
Current Ratio	0.11
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.68
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- 49.85%
Sales past 3/5Y	13.88% 13.21%
EPS Y/Y TTM	47.25%
Sales Y/Y TTM	-58.14%
EPS Q/Q	101.82%
Sales Q/Q	-5.30%
Earnings	-
EPS/Sales Surpr.	-36.00% -

Insider Own	61.93%
Insider Trans	0.00%
Inst Own	6.68%
Inst Trans	0.03%
ROA	-42.70%
ROE	-
ROIC	-218.95%
Gross Margin	-17.00%
Oper. Margin	-264.26%
Profit Margin	-248.05%
SMA20	-23.72%
SMA50	-19.43%
SMA200	-4.50%
Trades

Shs Outstand	29.28M
Shs Float	12.36M
Short Float	3.17%
Short Ratio	0.10
Short Interest	0.39M
52W High	2.55 -58.82%
52W Low	0.56 87.47%
Volatility	14.30% 10.67%
ATR (14)	0.15
RSI (14)	38.83
Beta	0.81
Rel Volume	0.04
Avg Volume	3.84M
Volume	144,736

Perf Week	-21.05%
Perf Month	-8.70%
Perf Quarter	40.00%
Perf Half Y	-6.25%
Perf YTD	-5.41%
Perf Year	-47.66%
Perf 3Y	-55.53%
Perf 5Y	-98.48%
Perf 10Y	-
Recom	2.00
Target Price	6.00
Prev Close	1.02
Price	1.05
Change %	2.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-30-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$5 → $1
Dec-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jun-22-22	Initiated	H.C. Wainwright	Buy	$15
Apr-06-22	Downgrade	Truist	Buy → Hold	$10
Jan-28-22	Initiated	Oppenheimer	Outperform	$9
Nov-24-21	Initiated	Morgan Stanley	Equal-Weight	$9

Today 08:00AM	Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement (GlobeNewswire)
Sep-30-26 11:57AM	Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner (GlobeNewswire)
Sep-29-26 08:30AM	Celularity Announces Naveen Jain to Join Board of Directors (GlobeNewswire)
Sep-24-26 09:15AM	Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements (GlobeNewswire) +14.78%
Aug-27-26 10:27AM	Celularity Signs U.S. Manufacturing Collaboration With Potential $300 Million Purchase Opportunity (InvestorsHub) +138.53%
09:00AM	Loading…
09:00AM	Celularity and MuseCell Innovations Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell Platform (Business Wire)
Aug-25-26 07:59PM	Celularity Provides Update Regarding Nasdaq Listing Compliance (GlobeNewswire) +9.94%
Aug-17-26 10:54AM	NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp (InvestorsHub)
Jun-04-26 08:00AM	Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies (GlobeNewswire)
Jun-03-26 04:15PM	Celularity Releases CEO Letter to Shareholders (GlobeNewswire)
08:00AM	Celularity Appoints Rick Gonzalez as Chief Commercial Officer (GlobeNewswire)
May-29-26 05:15PM	Celularity Receives Nasdaq Notice Regarding Form 10-Q (GlobeNewswire) +5.94%
May-01-26 04:30PM	Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation (GlobeNewswire)
Apr-21-26 08:30AM	NEXGEL, Inc. Q4 2025 Earnings Call Summary (Moby)
08:30AM	Celularity Announces Closing of Transaction with NexGel (GlobeNewswire)
04:35PM	Loading…
Apr-17-26 04:35PM	Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing (GlobeNewswire)
Mar-12-26 08:30AM	Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities (GlobeNewswire)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-10-26 08:30AM	EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue (Benzinga) +11.20%
08:30AM	Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy (GlobeNewswire)
Feb-10-26 08:30AM	Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses (GlobeNewswire)
Dec-26-25 08:30AM	Celularity CEO Comments on Centers for Medicare & Medicaid Services' Withdrawal of Skin Substitute Local Coverage Determinations (GlobeNewswire)
Dec-22-25 04:01PM	Celularity Announces Closing of Financing Transactions (GlobeNewswire) -8.97%
Dec-18-25 02:10PM	Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision (GlobeNewswire)
Oct-30-25 08:00AM	Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care (GlobeNewswire)
Oct-14-25 08:45AM	Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease (GlobeNewswire) +11.27%
Sep-03-25 08:00AM	Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance (GlobeNewswire)
Aug-22-25 05:30PM	Celularity Receives Nasdaq Notice Regarding Form 10-Q (GlobeNewswire)
Aug-18-25 08:00AM	Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt (GlobeNewswire) +19.25%
Jul-09-25 08:30AM	Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law (GlobeNewswire) +12.17%
08:30AM	Loading…
Jul-01-25 08:30AM	Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies (GlobeNewswire)
Jun-10-25 04:15PM	Celularity Announces Chief Financial Officer Transition (GlobeNewswire) -10.45%
Jun-02-25 08:00AM	Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology (GlobeNewswire) +6.16%
May-30-25 05:30PM	Celularity Receives Nasdaq Notice Regarding Form 10-Q (GlobeNewswire) -7.46%
May-09-25 09:15AM	Celularity Announces Full Year 2024 Operating and Financial Results (GlobeNewswire)
Apr-25-25 05:30PM	Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees (GlobeNewswire)
Apr-14-25 08:00AM	Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products (GlobeNewswire)
Apr-07-25 08:00AM	Celularity Announces Publication of Senescence, NK cells, and cancer: navigating the crossroads of aging and disease in the April 4, 2025, Issue of Frontiers in Immunology (GlobeNewswire)
Feb-25-25 08:00AM	Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft Wound Care Products (GlobeNewswire) -9.37%
Feb-24-25 08:00AM	Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company (GlobeNewswire)
Jan-27-25 08:00AM	MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs (GlobeNewswire)
Dec-10-24 08:00AM	Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter (GlobeNewswire)
Dec-06-24 08:00AM	Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023 (GlobeNewswire)
Nov-27-24 05:00PM	Celularity Inc. Announces Receipt of Nasdaq Notification (GlobeNewswire) -29.47%
Nov-20-24 08:30AM	Celularitys Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific (GlobeNewswire)
08:30AM	Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell and Regenerative Medicine Center in Asia Pacific (GlobeNewswire)
Nov-18-24 08:30AM	Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter (GlobeNewswire) +12.60%
Nov-07-24 08:00AM	Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million (GlobeNewswire) +113.10%
Oct-23-24 08:30AM	Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel (GlobeNewswire) +7.06%
Oct-22-24 08:30AM	Celularity Provides Corporate Update (GlobeNewswire)
Oct-18-24 06:00PM	Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal (GlobeNewswire) -16.14%
Oct-16-24 05:15PM	Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound Product from Sequence LifeScience, Inc. (GlobeNewswire) -6.47%
Sep-05-24 04:05PM	Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 04:45PM	Celularity Appoints Richard J. Berman to its Board of Directors (GlobeNewswire)
Aug-23-24 05:00PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Jul-31-24 08:30AM	Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023 (GlobeNewswire) +5.35%
Jun-03-24 08:38AM	Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-24-24 05:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
May-14-24 09:15AM	Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy (GlobeNewswire) +25.95%
Apr-22-24 08:00AM	Celularity Inc. to Host Investor and Analyst Research & Development Day (GlobeNewswire)
Apr-19-24 05:30PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing (GlobeNewswire) -5.61%
Apr-18-24 04:30PM	Celularity Abstract Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials Accepted at ORS Tendon Conference 2024 (GlobeNewswire)
Apr-15-24 08:00AM	Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products (GlobeNewswire)
Apr-08-24 09:00AM	Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells (GlobeNewswire)
Mar-26-24 09:00AM	Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L (GlobeNewswire)
Mar-20-24 09:15AM	Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy (GlobeNewswire)
Mar-14-24 09:15AM	Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit (GlobeNewswire)
Mar-12-24 09:20AM	Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress (GlobeNewswire) -15.30%
Mar-07-24 09:35AM	Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells (GlobeNewswire) +27.67%
Feb-23-24 04:10PM	Celularity Announces 1-for-10 Reverse Stock Split (GlobeNewswire) +7.13% -9.56%
Feb-14-24 04:05PM	Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease (GlobeNewswire)
Feb-01-24 09:00AM	Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline (GlobeNewswire) +28.45%
Jan-25-24 09:00AM	Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions (GlobeNewswire) +16.00%
Jan-18-24 01:40PM	Celularity Releases CEO Letter to Shareholders (GlobeNewswire) +53.48%
Jan-04-24 01:00PM	Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare (GlobeNewswire) -9.25%
Jan-03-24 07:30PM	BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare (PR Newswire)
12:00PM	Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 (GlobeNewswire)
Nov-24-23 01:15PM	Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing (GlobeNewswire)
Oct-18-23 09:00AM	Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification (GlobeNewswire) -8.35%
Sep-07-23 04:10PM	Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors (GlobeNewswire)
Aug-29-23 09:00AM	Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron (GlobeNewswire) +8.04%
Jul-27-23 09:07AM	Celularity Inc. Announces $3 Million Registered Direct Offering (GlobeNewswire) +9.57%
09:00AM	Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications (GlobeNewswire)
Jul-18-23 09:00AM	Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies (GlobeNewswire) +5.71%
Jun-29-23 04:05PM	Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics (GlobeNewswire) +5.89%
Jun-01-23 09:15AM	Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability (GlobeNewswire) -8.71%
May-23-23 10:56AM	CELULARITY ANNOUNCES $45 MILLION PURCHASE ORDER, FIRST MIDDLE EAST PRIVATE LABEL AGREEMENT FOR CELULARITY'S HALAL-CERTIFIED BIOMATERIAL PRODUCTS (PR Newswire)
May-19-23 04:21PM	Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohns Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation (GlobeNewswire) +11.27%
May-10-23 09:00AM	Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products (GlobeNewswire) +10.18%
May-01-23 04:01PM	Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy (GlobeNewswire) -8.79%
Apr-27-23 09:00AM	Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia (GlobeNewswire)
Apr-12-23 09:00AM	Celularitys Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference Beyond Longevity: Live 120 Like 50 (GlobeNewswire)
Apr-05-23 09:00AM	Celularity Inc. Announces $6 Million Registered Direct Offering (GlobeNewswire) -11.48%
Apr-04-23 09:00AM	Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting (GlobeNewswire)
Apr-03-23 09:00AM	Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularitys Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDAs Center For Devices And Radiological Health (GlobeNewswire) +19.41%
Mar-28-23 10:55AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt (PR Newswire)
09:00AM	Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt (GlobeNewswire)
Feb-02-23 07:53AM	Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire)
Feb-01-23 04:05PM	Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) (GlobeNewswire) +8.50%
Jan-26-23 04:17PM	Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates (GlobeNewswire) +7.68%

Show Previous News

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Brigido Stephen	Pres., Functional Regeneration	Apr 13 '26	Option Exercise	821	9,742	Apr 15 04:30 PM
Haines John R	Senior Exec Vice President	Apr 13 '26	Option Exercise	1,641	30,762	Apr 15 04:30 PM
Hariri Robert J	Chief Executive Officer	Apr 13 '26	Option Exercise	3,281	2,854,735	Apr 15 04:30 PM

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

Ph.D.Dr. Robert Joseph Hariri M.D.

Acting Chief Financial OfficerJohn Sprague

Chief Operating and Administrative Officer & DirectorMr. Steven N. Gordon Esq.

SVP of Investor RelationsMr. Carlos Ramirez

Chief Legal and Strategy Officer & Corporate SecretaryMr. Kyle Harold Fletcher Esq.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELU

Celularity Inc

Upgrade your Finviz experience